NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 318 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,360,137 | -58.0% | 84,219 | +8.0% | 0.01% | -64.1% |
| Q2 2023 | $3,234,884 | +84961.4% | 77,949 | +23.3% | 0.04% | -33.9% |
| Q1 2023 | $3,803 | +93.0% | 63,232 | +135.5% | 0.06% | +51.3% |
| Q4 2022 | $1,970 | -99.9% | 26,855 | -36.2% | 0.04% | -49.4% |
| Q2 2022 | $2,924,000 | +1003.4% | 42,073 | +1091.5% | 0.08% | +1825.0% |
| Q4 2021 | $265,000 | -77.4% | 3,531 | -33.4% | 0.00% | -81.8% |
| Q2 2021 | $1,175,000 | -56.1% | 5,298 | -65.8% | 0.02% | -71.1% |
| Q4 2020 | $2,677,000 | +29.8% | 15,472 | -55.5% | 0.08% | -25.5% |
| Q2 2020 | $2,063,000 | +766.8% | 34,795 | +886.0% | 0.10% | +385.7% |
| Q1 2020 | $238,000 | -70.1% | 3,529 | -62.7% | 0.02% | -41.7% |
| Q4 2019 | $797,000 | -58.1% | 9,453 | -68.6% | 0.04% | -33.3% |
| Q2 2019 | $1,903,000 | -18.5% | 30,096 | -37.9% | 0.05% | -44.3% |
| Q1 2019 | $2,335,000 | +1097.4% | 48,470 | +190.2% | 0.10% | +2325.0% |
| Q2 2016 | $195,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |